Norges Bank Atea Pharmaceuticals, Inc. Transaction History

Norges Bank

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$2.8 - $3.35 $101,360 - $121,270	36,200 New	36,200 $110,000
Q3 2023 Nov 13, 2024	BUY	$3.0 - $3.79 $108,600 - $137,198	36,200 New	36,200 $108,000
Q2 2023 Aug 14, 2024	BUY	$3.21 - $5.06 $118,449 - $186,714	36,900 New	36,900 $138,000
Q1 2023 May 15, 2024	BUY	$3.0 - $4.97 $612,600 - $1.01 Million	204,200 New	204,200 $684,000
Q4 2022 Feb 14, 2023	BUY	$4.35 - $6.17 $888,269 - $1.26 Million	204,200 New	204,200 $982,000
Q1 2022 May 09, 2022	SELL	$5.5 - $9.19 $600,022 - $1 Million	-109,095 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$7.67 - $44.59 $836,758 - $4.86 Million	109,095 New	109,095 $975,000
Q3 2021 Nov 14, 2022	BUY	$21.33 - $35.06 $2.33 Million - $3.82 Million	109,095 New	109,095 $3.83 Million
Q3 2021 Nov 05, 2021	SELL	$21.33 - $35.06 $13.8 Million - $22.7 Million	-646,362 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$19.22 - $59.08 $12.4 Million - $38.2 Million	646,362 New	646,362 $13.9 Million
Q1 2021 May 07, 2021	SELL	$41.42 - $88.44 $1.24 Million - $2.65 Million	-30,000 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$26.36 - $41.78 $790,800 - $1.25 Million	30,000 New	30,000 $1.25 Million

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $275M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.